Over 537 million people globally suffer from diabetes, with 227 million in Asia Pacific. More than half may develop diabetic ...

Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 ...

OCX-063 is under clinical development by OccuRx and currently in Phase I for Diabetic Retinopathy. According to GlobalData, Phase I drugs for Diabetic Retinopathy have a 78% phase transition success ...

APX-3330 is under clinical development by Opus Genetics and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR).

Empagliflozin initiation is not associated with incident nonproliferative diabetic retinopathy (NPDR) compared with ...

下面我就来说说对糖尿病患者视力影响最严重、生活质量影响最明显的几种眼病。

Keep abreast with the latest news related to Diabetic Retinopathy there are 3171 news items on Diabetic Retinopathy that covers updates, breakthroughs and in-depth reports. We provide you with a ...